×
About 5,000 results

ALLMedicine™ Splenomegaly Center

Research & Reviews  1,732 results

Nuclear factor of activated T cells 4 in the prefrontal cortex is required for prophyla...
https://doi.org/10.1038/s41398-022-01803-6
Translational Psychiatry; Ma L, Zhang J et. al.

Jan 23rd, 2022 - (R, S)-ketamine has prophylactic antidepressant-like effects in rodents; however, the precise molecular mechanisms underlying its action remain unknown. Using RNA-sequencing analysis, we searched novel molecular target(s) that contribute to the pr...

Introduction to a Special Issue on Low-Grade B Cell Lymphoma in the Spleen.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774332
Current Oncology (Toronto, Ont.); Nava VE

Jan 21st, 2022 - Malignant lymphoproliferative disorders in the spleen may be primary (usually designated as splenic lymphoma) or secondary (due to progression of nodal or extra nodal lymphoid neoplasms) and represent an underestimated cause of splenomegaly, parti...

Peripheral neuropathy as a very rare symptom in a patient with Niemann-Pick type C with...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753839
Journal of Medical Case Reports; Barzegar M, Valaee F et. al.

Jan 13th, 2022 - Niemann-Pick is a rare metabolic disease distinguished by lysosomal storage defects. This disease is characterized by sphingomyelinase acid deficiency, causing its accumulation in various organs such as the kidneys, spleen, liver, brain, and nerve...

Elevated granulocyte-colony stimulating factor and hematopoietic stem cell mobilization...
https://doi.org/10.1016/j.jlr.2021.100167
Journal of Lipid Research; Groenen AG, La Rose AM et. al.

Jan 11th, 2022 - Niemann-Pick Type C1 (NPC1) disease is a progressive lysosomal storage disorder caused by mutations of the NPC1 gene. While neurodegeneration is the most severe symptom, a large proportion of NPC1 patients also present with splenomegaly, which has...

see more →

Guidelines  1 results

Revised diagnostic criteria and classification for the autoimmune lymphoproliferative s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953894
Blood Oliveira JB, Bleesing JJ et. al.

Jun 12th, 2010 - Lymphadenopathy in children for which no infectious or malignant cause can be ascertained constitutes a challenging diagnostic dilemma. Autoimmune lymphoproliferative syndrome (ALPS) is a human genetic disorder of lymphocyte apoptosis resulting in...

see more →

Drugs  11 results see all →

Clinicaltrials.gov  28 results

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors
https://clinicaltrials.gov/ct2/show/NCT05153343

Dec 10th, 2021 - Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). FM is a dual target inhibitor of JAK2/FLT3.FM has the activity of inhibiting JAK2 signaling pathway, and pharmacodynamics evaluation also confirmed that ...

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors
https://clinicaltrials.gov/ct2/show/NCT05115344

Nov 10th, 2021 - Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). FM is a dual target inhibitor of JAK2/FLT3.FM has the activity of inhibiting JAK2 signaling pathway, and pharmacodynamics evaluation also confirmed that ...

A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism
https://clinicaltrials.gov/ct2/show/NCT05055713

Oct 28th, 2021 - Although there have been many consensus opinions on the treatment of cirrhosis patients with esophageal and gastric variceal hemorrhage, there is no standard to follow for the treatment of cirrhosis patients with esophageal and gastric variceal he...

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-e...
https://clinicaltrials.gov/ct2/show/NCT03952039

Sep 22nd, 2021 - This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombo...

Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis
https://clinicaltrials.gov/ct2/show/NCT04631458

Sep 16th, 2021 - Study Title Morbidity and portal circulation in patients with Myeloproliferative neoplasms and splanchnic vein thrombosis: Mascot Protocol No. MPN-SVT v11; 02/Dec/2013 Study Design Prospective observational longitudinal study of patients with MPN ...

see more →

News  225 results

Widespread Necrotizing Purpura and Lucio Phenomenon as the First Diagnostic Presentation of Diffuse Nonnodular Lepromatous Leprosy
https://www.mdedge.com/dermatology/article/249886/infectious-diseases/widespread-necrotizing-purpura-and-lucio-phenomenon
Amira Shahin, MD, Randa Yousef, MD et. al.

Dec 14th, 2021 - Case Report A 70-year-old man living in Esna, Luxor, Egypt presented to the Department of Rheumatology and Rehabilitation with widespread gangrenous skin lesions associated with ulcers of 2 weeks’ duration. One year prior, the patient had an insid.

A Fatal Case of Hemophagocytic Lymphohistiocytosis Secondary to Anti-MDA5–Positive Dermatomyositis
https://www.mdedge.com/dermatology/article/249873/rare-diseases/fatal-case-hemophagocytic-lymphohistiocytosis-secondary
Alexandria Riopelle, MD, Joseph Zikry, MD et. al.

Dec 13th, 2021 - To the Editor: Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by bilateral, symmetrical, proximal muscle weakness and classic cutaneous manifestations. 1 Patients with antibodies directed against melanoma differentiation–.

Dr. Harrison on the Current State of Treatment in Myelofibrosis
https://www.onclive.com/view/dr-harrison-on-the-current-state-of-treatment-in-myelofibrosis

Dec 13th, 2021 - Claire Harrison, MD, FRCP, FRCPath, professor of myeloproliferative neoplasms, clinical director, NHS Guy’s and St Thomas’ NHS Foundation Trust, discusses the current state of treatment in myelofibrosis. Treatment selection for patients with my...

Counseling Patients With Newly Diagnosed CLL
https://www.onclive.com/view/counseling-patients-with-newly-diagnosed-cll

Dec 7th, 2021 - Anthony Mato, MD, MSCE: Of course, we get all these results back. Some are complicated. We do detail next-generation sequencing, we do FISH [fluorescence in situ hybridization], cytogenetics, IGHV testing—they’re obviously confusing to patients. W...

FDA Approves Ropeginterferon Alfa-2b-njft for Polycythemia Vera
https://www.onclive.com/view/fda-approves-ropeginterferon-alfa-2b-njft-for-polycythemia-vera

Nov 13th, 2021 - The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for use as a treatment in patients with polycythemia vera.1 The regulatory decision was based on safety from the PEGINVERA and PROUD/ CONTINUATION-PV studies and efficacy findings from t...

see more →

Patient Education  3 results see all →